As a multiple target TKI, all the target molecules (e.g., VEGFR 1 to 3, EGFR, PDGFR-α and -β and FGFR 1–3) of anlotinib can contribute to its inhibitory action on tumor angiogenesis and affect tumor cell growth function (Lin et al., 2018; Taurin et al., 2018; Chen, 2019). The gene discussed is EGFR; the disease is neoplasm.